Clinical Trials

AI Revolutionizes Drug Development with NVIDIA and IQVIA Partnership
Management & Regulatory AI Revolutionizes Drug Development with NVIDIA and IQVIA Partnership

The pharmaceutical industry, often characterized by lengthy and costly drug development cycles, is on the brink of a revolutionary shift. A strategic partnership between IQVIA, a leader in clinical research services, and NVIDIA, a cutting-edge technology company renowned for AI innovations,

Can Trust Rebuild Diversity in Clinical Trials?
Research & Development Can Trust Rebuild Diversity in Clinical Trials?

In recent years, the underrepresentation of minority groups in clinical trials has emerged as a critical issue in medical research. Despite various interventions designed to increase participation from these communities, the numbers have not seen significant improvement. The challenge is not rooted

Can AI-Driven Imaging Transform Cancer Surgery Outcomes?
Tech & Innovation Can AI-Driven Imaging Transform Cancer Surgery Outcomes?

The landscape of cancer surgery is witnessing a significant transformation with the integration of artificial intelligence in medical imaging. These advanced technologies hold the potential to revolutionize cancer surgery by enhancing precision and improving patient outcomes. Perimeter Medical

Is GAL-101 the Future of AMD Treatment?
Research & Development Is GAL-101 the Future of AMD Treatment?

The world of ophthalmology faces a promising yet complex challenge as it navigates the treatment of age-related macular degeneration (AMD), a leading cause of vision loss across the globe. In recent years, advancements in medical research have unveiled new pathways to tackle this degenerative

Why Are Obesity Medications Less Effective in Real Life?
Research & Development Why Are Obesity Medications Less Effective in Real Life?

A recent study conducted by the Cleveland Clinic sheds light on the real-world challenges faced by injectable medications used for obesity treatment, namely semaglutide and tirzepatide. These medications, approved by the FDA for both obesity management and type 2 diabetes care, are marketed under

Will Aumseqa Revolutionize NSCLC Treatment with EGFR Mutation?
Management & Regulatory Will Aumseqa Revolutionize NSCLC Treatment with EGFR Mutation?

In the rapidly evolving landscape of cancer treatments, Aumseqa (aumolertinib) has emerged as a promising advancement against non-small cell lung cancer (NSCLC) characterized by EGFR mutations. Recently approved by the Medicines and Healthcare products Regulatory Agency (MHRA), Aumseqa is

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later